We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

By LabMedica International staff writers
Posted on 20 Feb 2026

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging for biomarker discovery and diagnostic development. More...

Laboratories also require scalable extraction methods that accommodate variable input volumes and multiple biofluids while preserving reproducibility and workflow efficiency. A newly introduced extraction kit addresses these needs by enabling consistent, automation-ready isolation of cfDNA from commonly used biofluids.

New England Biolabs (Ipswich, MA, USA) has launched the Monarch Mag Cell-free DNA (cfDNA) Extraction Kit for the isolation of low-abundance circulating DNA from a range of biofluids. The kit supports plasma, serum, urine and cerebrospinal fluid inputs ranging from 1 mL to 4 mL. It is positioned for workflows spanning manual processing to higher throughput with automation, and for use prior to applications including biomarker discovery and diagnostics development.

The technology employs a magnetic bead–based approach that combines specialized chemistry with silica-coated magnetic particles to efficiently recover short DNA fragments from challenging matrices, including those with high nuclease activity. Designed for automation compatibility, the streamlined workflow delivers consistent, concentrated cfDNA suitable for a broad range of downstream molecular analyses. Reported performance demonstrates recovery across the full spectrum of fragment sizes, including fragments as small as 50 base pairs.

For laboratories aiming to streamline sample‑to‑result pipelines, the kit pairs with the company’s downstream amplification and library preparation products, including the NEBNext portfolio for next generation sequencing library preparation. The format is intended to offer versatility across sample numbers, input amounts and sample types while maintaining reproducibility. Packaging updates within the Monarch portfolio reduce plastic usage in reagent bottles and packaging components compared to standard market solutions.

“Extracting cell-free DNA is uniquely challenging because it is highly fragmented and circulating at low concentrations within complex and variable biofluid matrices,” stated Anagha Kadam, Applications and Product Development Scientist II at NEB. “The kit utilizes a specialized chemistry and silica-coated magnetic beads to efficiently recover short DNA fragments from challenging samples that inherently exhibit high nuclease activity.”

“Bouncing between vendors to troubleshoot an issue is exhausting and inefficient,” said James Deng, Senior Product Marketing Manager for NEB. “With a cfDNA extraction kit that integrates seamlessly into our downstream sequencing and amplification solutions, we’re empowered to more holistically address customer challenges from sample preparation through molecular diagnostic applications.”

Related Links
New England Biolabs


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
New
Automated Immunoassay Analyzer
SuperFlex™
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.